Fig. 3. Overall survival (A) and disease-free survival (B) of FB-GBC and NC-GBC for all patients (n = 372). The NC-GBC group showed a significant poor prognosis in the 5-year overall survival rate (76.7% vs. 45.0%, p < 0.001) and disease-free survival rate (68.7% vs. 25.0%, p < 0.001), compared to the FB-GBC group. FB-GBC, gallbladder cancer in the fundus/body; NC-GBC, gallbladder cancer in the neck/cystic duct; 5-YSR, 5-year survival rate.